子痫前期孕妇外周血游离DNA的研究进展

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (12): 1701-1705.

子痫前期孕妇外周血游离DNA的研究进展

周嘉怡, 吴逊伟, 戴莉娟, 赵瑰丽, 余波澜^*

广州医科大学附属第三医院广东省产科重大疾病重点实验室广东省母胎医学工程技术研究中心,广东广州 510150

收稿日期:2019-06-21 修回日期:2020-01-18 出版日期:2020-12-05 发布日期:2020-11-30
通讯作者: ^* yubolan-q@qq.com
基金资助:
国家科技部重点研发计划(2018YFC1004104);广州市科技计划重点项目(201804020057);广东省科技厅公益研究与能力建设项目(2019B030316023)

Research progress of peripheral blood free DNA in preeclampsia pregnancy

ZHOU Jia-yi, WU Xun-wei, DAI Li-juan, ZHAO Gui-li, YU Bo-lan^*

Guangdong Maternal-Fetal Medical Engineering Research Center, Guangdong Key Laboratory of Obstetrics and Major Diseases, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China

Received:2019-06-21 Revised:2020-01-18 Online:2020-12-05 Published:2020-11-30
Contact: ^* yubolan-q@qq.com

摘要/Abstract

摘要： 妊娠高血压疾病,尤其是子痫前期(PE),是世界范围内孕产妇和围产期发病率和病死率增加的主要原因之一。而孕妇血液胎儿游离的DNA(cff-DNA)可作为早期预测PE的发生发展。并且总结分析cff-DNA与PE的相关性及其可能存在的机制,进一步说明PE的发生可能与DNA甲基化相关,同时探讨其作为生物标志物的局限性,为有效预测子痫前期提供参考。

关键词: 外周游离核酸, 子痫前期, 生物标志物

Abstract: Pregnancy-induced hypertension, especially preeclampsia (PE), is one of the leading causes of increased maternal and perinatal morbidity and mortality worldwide. And the circulating cell free fetal nucleic acid (cff-DNA) analysis of pregnant women can be used as an early prediction of the occurrence and development of PE. By summarizing and analyzing the correlation between cff-DNA and PE and its possible mechanism, this paper further explained that the occurrence of PE may be related to DNA methylation, and discussed its limitations as a biomarker, so as to provide reference for the effective prediction of preeclampsia.

Key words: cell free fetal nucleic acid, preeclampsia, biomarker

中图分类号:

R714
R44

周嘉怡, 吴逊伟, 戴莉娟, 赵瑰丽, 余波澜. 子痫前期孕妇外周血游离DNA的研究进展[J]. 基础医学与临床, 2020, 40(12): 1701-1705.

ZHOU Jia-yi, WU Xun-wei, DAI Li-juan, ZHAO Gui-li, YU Bo-lan. Research progress of peripheral blood free DNA in preeclampsia pregnancy[J]. Basic & Clinical Medicine, 2020, 40(12): 1701-1705.

参考文献

[1] Walknowska J, Conte FA, Grumbach MM. Practical and theoretical implications of fetal-maternal lymphocyte transfer[J]. Lancet, 1969, 1: 1119-1122.
[2] Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum[J]. Lancet, 1997, 350: 485-487.
[3] Gillon TE, Pels A, von Dadelszen P, et al. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines[J]. PLoS One, 2014, 9: e113715.doi: 10.1371/journal.pone.0113715.
[4] Bender WR, Koelper NC, Sammel MD, et al. Association of fetal fraction of cell-free DNA and hypertensive disorders of pregnancy[J]. Am J Perinatol, 2019, 36: 311-316.
[5] Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP[J]. Pregnancy Hypertens, 2014, 4: 97-104.
[6] Granger JP, Alexander BT, Bennett WA, et al. Pathophysiology of pregnancy-induced hypertension[J]. Am J Hypertens, 2001, 14: 178s-185s.
[7] Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors and preeclampsia[J]. Front Biosci, 2007, 12: 2395-2402.
[8] Mol BWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia[J]. Lancet, 2016, 387: 999-1011.
[9] Naljayan MV, Karumanchi SA. New developments in the pathogenesis of preeclampsia[J]. Adv Chronic Kidney Dis, 2013, 20: 265-270.
[10] Kohli S, Ranjan S, Hoffmann J, et al. Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts[J]. Blood, 2016, 128: 2153-2164.
[11] He B, Yang X, Li Y, et al. TLR9 (Toll-Like Receptor 9) agonist suppresses angiogenesis by differentially regulating VEGFA (vascular endothelial growth factor A) and sFLT1 (soluble vascular endothelial growth factor receptor 1) in preeclampsia[J]. Hypertension, 2018, 71: 671-680.
[12] van Boeckel SR, Davidson DJ, Norman JE, et al. Cell-free fetal DNA and spontaneous preterm birth[J]. Reproduction, 2018, 155: R137-R145.
[13] Sur Chowdhury C, Hahn S, Hasler P, et al. Elevated levels of total cell-free DNA in maternal serum samples arise from the generation of neutrophil extracellular traps[J]. Fetal Diagn Ther, 2016, 40: 263-267.
[14] Eche S, Mackraj I, Moodley J. Circulating fetal and total cell-free DNA, and sHLA-G in black South African women with gestational hypertension and pre-eclampsia[J]. Hypertens Pregnancy, 2017, 36: 295-301.
[15] Vinnars MT, Nasiell J, Ghazi S, et al. The severity of clinical manifestations in preeclampsia correlates with the amount of placental infarction[J]. Acta Obstet Gynecol Scand, 2011, 90: 19-25.
[16] Rolnik DL, da Silva Costa F, Lee TJ, et al. Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia[J]. Ultrasound Obstet Gynecol, 2018, 52: 722-727.
[17] Poon LL, Leung TN, Lau TK, et al. Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma[J]. Clin Chem, 2002, 48: 35-41.
[18] Majchrzak-Celinska A, Kosicka K, Paczkowska J, et al. HSD11B2, RUNX3, and LINE-1 methylation in placental DNA of hypertensive disorders of pregnancy patients[J]. Reprod Sci, 2017, 24: 1520-1531.
[19] Chen X, Xiong L, Zeng T, et al. Hypermethylated ERG as a cell-free fetal DNA biomarker for non-invasive prenatal testing of Down syndrome[J]. Clin Chim Acta, 2015, 444: 289-292.
[20] Dokras A, Gardner LM, Kirschmann DA, et al. The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development[J]. Placenta, 2002, 23: 274-280.
[21] Chim SS, Tong YK, Chiu RW, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma[J]. Proc Natl Acad Sci U S A, 2005, 102: 14753-14758.
[22] Shi X, Liu H, Cao J, et al. Promoter hypomethylation of maspin inhibits migration and invasion of extravillous trophoblast cells during placentation[J]. PLoS One, 2015, 10: e0135359.doi:10.1371/joumal.pone.0135359.
[23] Qi YH, Teng F, Zhou Q, et al. Unmethylated-maspin DNA in maternal plasma is associated with severe preeclampsia[J]. Acta Obstet Gynecol Scand, 2015, 94: 983-988.
[24] Rahat B, Thakur S, Bagga R, et al. Epigenetic regulation of STAT5A and its role as fetal DNA epigenetic marker during placental development and dysfunction[J]. Placenta, 2016, 44: 46-53.
[25] Zadora J, Singh M, Herse F, et al. Disturbed placental imprinting in preeclampsia leads to altered expression of DLX5, a human-specific early trophoblast marker[J]. Circulation, 2017, 136: 1824-1839.